Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Pharmacyclics LLC et al v. Alvogen Pine Brook LLC et al
Case Number:
1:19-cv-00434
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
Companies
Sectors & Industries:
-
April 30, 2024
Pharmacyclics Can't Score Fees After Imbruvica Patent Win
Delaware's top federal judge on Tuesday told AbbVie's Pharmacyclics LLC unit that it was "also guilty of vexatious conduct" and had no standing to seek legal fees after it won a patent infringement suit against generic-drug rivals over its branded blockbuster cancer drug Imbruvica.
-
February 22, 2023
AbbVie, J&J Units Say Del. Judge's Rebukes Bolster Fee Bid
Pharmacyclics LLC and Janssen Biotech Inc. are urging a Delaware federal judge to grant them fees after their win in patent infringement litigation over the cancer drug Imbruvica, noting the judge himself repeatedly lost patience with the losing companies.
-
October 07, 2022
Alvogen Continues IP Fight Over Cancer Drug Imbruvica
In a rematch over the leukemia medication Imbruvica, AbbVie's Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech urged the Federal Circuit Friday to uphold a lower court ruling that their four patents related to the blockbuster drug are valid.
-
August 19, 2021
AbbVie, Janssen Win IP Fight Over Cancer Drug Imbruvica
A Delaware federal judge on Thursday ruled in favor of AbbVie and Janssen Biotech Inc. in their 2019 suit against Alvogen over its planned generic version of the blockbuster cancer drug Imbruvica, holding that all four patents in the case were not shown to be invalid.